Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  20.20 1.32% 1,554.80 5,335,382 16:35:14
Bid Price Offer Price High Price Low Price Open Price
1,557.00 1,557.60 1,565.80 1,540.60 1,542.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 16.6 78,223
Last Trade Time Trade Type Trade Size Trade Price Currency
17:47:27 O 30,152 1,542.40 GBX

Glaxosmithkline (GSK) Latest News

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 5.99% 2021-10-31

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline Forums and Chat

Date Time Title Posts
06/12/202110:47Glaxosmithkline - The recovery28,940
24/8/202112:00GlazoSmithKline - News & Information75
02/7/202109:58GSK - just mucking around-
23/1/202114:27In Rude Health!1

Add a New Thread

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-12-06 17:30:581,557.4725,938403,977.09O
2021-12-06 17:30:501,554.80133,4292,074,554.09O
2021-12-06 17:28:281,555.2919,187298,414.26O
2021-12-06 17:25:021,544.096,20095,733.52O
2021-12-06 17:21:231,558.952,53539,519.48O
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,534.60p.
Glaxosmithkline Plc has a 4 week average price of 1,503p and a 12 week average price of 1,362.80p.
The 1 year high share price is 1,604.40p while the 1 year low share price is currently 1,190.80p.
There are currently 5,031,076,193 shares in issue and the average daily traded volume is 9,760,414 shares. The market capitalisation of Glaxosmithkline Plc is £78,223,172,648.76.
fionascott1234: A GSK production of a cancer cure would obviously create a complete rout of the share price.
maxk: New antibody treatment that makers claim can tackle omicron approved by UK regulator Xevudy (sotrovimab), made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79 percent By Gareth Davies, BREAKING NEWS EDITOR 2 December 2021 • 8:34am A drug treatment which, the makers say, works against the new Omicron variant of Covid-19, has been approved by UK regulators. Xevudy (sotrovimab), made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79% in those at risk. The monoclonal antibody has been authorised by the Medicines and Healthcare products Regulatory Agency for people with mild to moderate Covid-19 who are at high risk of developing severe disease. It comes as GSK and Vir Biotechnology said preclinical data shows the drug "retains activity against key mutations of the new Omicron Sars-CoV-2 variant". The UK Government has ordered around 100,000 doses of the drug. More: https://www.telegraph.co.uk/news/2021/12/02/new-antibody-treatment-makers-claim-can-tackle-omicron-approved/
geckotheglorious: 3 stocks with recovery potential GlaxoSmithKline Pharmaceutical company GlaxoSmithKline is nearing a crucial turning point. The group’s embarking on a major strategy shift that will see the consumer business separated from pharmaceuticals. If successful, this should leave behind two better businesses with more manageable debt obligations. Strategy shifts of this scale rarely go off without a hitch though, which explains the group’s muted valuation. Its price to earnings ratio is currently at 13.2, roughly in line with the long-term average, but below that of peers. Glaxo’s net debt position is a whopping £22.1bn. With the prospect of rising interest rates on the horizon, this is a concern. However, NewGSK, which will be made up of the pharmaceutical business will strike out on its own with a relatively small debt pile, worth roughly two times cash profits. The rest will go to the newly single consumer healthcare business, whose relatively stable revenue and minimal investment requirements will make it more manageable to pay down over time. Shareholders get shares in both companies, but neither will pay a particularly impressive dividend. The prospective yield for both is 3.7%. That’s not nothing, but considering GSK shares have been yielding upwards of 5%, it’s understandably disappointing. Yields are variable and not guaranteed. But aside from the restructure’s impact on debt, there are some opportunities pinned to NewGSK. The group’s monoclonal antibodies treatment for Covid-19 could prove an important tool in the fight against coronavirus moving forward – particularly with evidence showing vaccine effectiveness fades over time. The US government has just placed a $1bn order for the treatment, and if coronavirus is to stick around, this could be the first of many. Plus, roughly a third of the group’s pipeline is in late-stage development and it’s also got a strong portfolio of patented respiratory and HIV drugs underpinning revenue. This is made all the more appealing when you look at GSK’s ability to turn sales into profits. With operating margins at 23%, the group’s ahead of peers. Return on equity, a measure that tells you how efficiently shareholder cash is turned into profits, is an impressive 44% – well beyond other industry leaders. GlaxoSmithKline has potential if all goes as planned over the next year. The ‘if’ is doing a lot of work here though. The drug approval process is uncertain at best, and there’s no guarantee the split will go off without a hitch. Still, we think GSK shares offer an opportunity for investors willing to stomach those risks. hTTps://www.hl.co.uk/news/articles/3-stocks-with-recovery-potential?
philanderer: After a meeting with the CFO, Berenberg believes ‘New GSK’ can hit targets of 5% plus revenue growth and 10% in operating profits over the next five years. In addition, GSK has several potential blockbusters in its pipeline with data readouts from a phase III trial of a new RSV vaccine in the first half of 2022 to be followed by read-outs from hepatitis B and arthritis developments. GSK’s two key COVID-19 vaccine partnerships meanwhile should release data, with nothing allowed for any success here in Berenberg’s price target of 1,630p. Buy is the broker’s view. proactiveinvestors.co.uk
medieval blacksmith: There will be an element of investors not wanting the price to go too high. They will be looking for the greatest ownership of the spin-off at the lowest price. An arbitrage at play here will be to buy into GSK with a view to owning the spin off having bought at low PEs in GSK as currently. Once the spin off happens they will sell GSK to offset costs of purchase in the new company. That is what I am doing. :)
porsche1945: BERENBERG SAYS GSK 'UNDERVALUED' BUT PIPELINE UNDERWHELMS (Sharecast News) - Analysts at Berenberg reduced their target price for shares of GlaxoSmithKline from 1,625.0p to 1,540.0p, but stood by their 'buy' recommendation on the shares, pointing out that the company's exit from its Consumer healthcare division was now closer and arguing that the stock remained "fundamentally undervalued". On the flip side, the pharmaceutical giant's pipeline had not played out as hoped in 2021. Berenberg also saw stasis on returns from GSK's investments in research and development. The analysts estimated that the company would generate a return from R&D investment of 6%, which was below its 8% cost of capital and in line with the previous two historical cohorts. "Time is running out for management to deliver positive pipeline progress. Without Consumer Healthcare from mid-2022, "New GSK" will be increasingly exposed to its pharma R&D fortunes," they added.
a0469514: From Bloomberg yesterdayPrivate equity firms are said to be on the hunt for the consumer unit of GlaxoSmithKline (NYSE:GSK), valuing it at 40 billion pounds ($54 billion) or more in what could be the biggest buyout deal of all time, Bloomberg reports.GlaxoSmithKline (GSK) ADRs have added ~2.6% in the pre-market.According to people familiar with the matter, Advent International, Blackstone Inc., Carlyle Group Inc., CVC Capital Partners, KKR & Co., and Permira are among those evaluating the business for which GlaxoSmithKline (GSK) had previously said it would pursue a separate listing in London.Alongside plans for a listing, the company advisors are said to be informally fielding interest for its operations, the people said on the condition of anonymity. The unit could attract some of the world's largest pharmaceutical and consumer goods makers, they added.The news of the buyout deal comes at a time GlaxoSmithKline (GSK) has increasingly come under activist pressure, with Bluebell Capital Partners becoming the latest hedge fund to seek changes at the British drugmaker.
tradermichael: Share price jump today ....... are we starting to see the start of the action: GSK shareholders will receive stock in the new consumer healthcare group amounting to at least 80% of the 68% stake that GSK currently owns in it. New GSK aims to sell the its remaining stake, described as a short-term investment, "in a timely manner," the group said. Based on brokerage Jefferies' valuation of 45 billion pounds for the whole consumer unit, that would be worth about 6 billion. Pfizer, owner of the remaining 32%, has also said it would seek an exit. Consumer Healthcare = $54 billion price tag projected .....
lancasterbomber: Elliott is thought to be frustrated at Sir Jonathan’s resistance to calls for boss Dame Emma Walmsley to effectively re-apply for her job By Oliver Gill, CHIEF BUSINESS CORRESPONDENT 25 September 2021 • 7:00pm GlaxoSmithKline is heading for a crunch meeting with investors as boss Dame Emma Walmsley clings on despite growing frustration from Wall Street activist Elliott. Sir Jonathan Symonds, chairman, and Vindi Banga, senior independent director and a consumer industry veteran, will set out their case to a host of City institutions, urging investors to support their plans to create two listed businesses. The meeting, hosted by influential shareholder group the Investor Forum on Oct 7, comes with tensions understood to be mounting between the board and Elliott. City sources said that Elliott is frustrated at Sir Jonathan’s resistance to calls for Dame Emma to effectively re-apply for her job. Elliott is understood to have been holding regular meetings with the company after building a multi billion-pound stake in the company in April. Under GSK’s current plans, Dame Emma will lead so-called New GSK - the pharmaceuticals arm - when the business is spun off next year. But Elliott wants the FTSE 100 firm to first bolster its board by hiring directors with pharmaceutical experience before running a new recruitment process for New GSK’s chief executive. The activist also wants the GSK board to consider selling the consumer arm instead of creating a separate listed company. Insiders said that company has put a £50bn price tag on the business, however, pricing all but a handful of suitors out of the market. Large private equity houses such as Blackstone and Carlyle are understood to consider the division too large to make an offer. A GSK spokesman said: “We continue to engage extensively with our shareholders with over 500 meetings so far this year. They have expressed widespread and strong support for our plans. “Our plan to de-merge our consumer healthcare business maximises value for shareholders. Our shareholders tell us they want to own the new consumer healthcare company as a listed entity and they want us to stick to the timetable for delivering it.
spud: A Big Pharma CEO Is Battling Wall Street’s Most Feared Fund http://www.bloomberg.com/news/features/2021-09-07/feared-wall-street-fund-elliott-is-targeting-gsk-what-does-it-want GSK’s Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from. One afternoon in mid-April, Emma Walmsley, the chief executive officer of GlaxoSmithKline Plc, logged into what could be one of the most important video conferences of her career. A few days earlier Elliott Investment Management, the U.S.-based activist fund, had contacted the drugmaker’s chairman, Jonathan Symonds, with some alarming news. Without GSK’s knowledge, Elliott had been quietly buying up billions of dollars of its shares. Now Gordon Singer, a managing partner at the firm and the son of its founder, Paul Singer, was going to explain why, and what Elliott wanted. No corporate leader relishes a call from Elliott, one of the most aggressive investors on the planet, with a long track record of forcing sales or breakups, ousting CEOs, overhauling boards—and even, on one occasion, seizing an Argentine naval vessel over a debt dispute. Walmsley and Symonds, however, were trying to be open-minded about what Singer had to say; under the circumstances, they didn’t have much choice. Over the next hour, Singer and a colleague, Sebastien De La Riviere, walked the GSK executives through a detailed presentation on their company. It followed a standard Elliott playbook, outlining what the fund viewed as a series of failings over the years, combined with examples of unflattering commentary from shareholders it had interviewed in the months it spent accruing its stake. Walmsley and Symonds listened politely. But no one on either side of the call was under any illusions: Elliott had just issued a direct challenge to Walmsley’s leadership. For the 52-year-old CEO, that represented a serious problem. Arguably the highest-profile female executive in Britain, Walmsley was partway through an elaborate effort to transform her vast company, spinning off its consumer business—the maker of Advil, Sensodyne, and Nicorette, among two dozen products—from the core pharmaceutical operation. Defending against an assault by Elliott was not part of the plan. And she’d be doing it in public: hours before the meeting, the Financial Times had revealed that Elliott was targeting GSK............. spud
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211207 06:38:21